An injectable combination of cabotegravir and rilpivirine (Cabenuva) safely maintained long-term viral suppression in adolescents with HIV who switched from daily oral medications.[1] The US Food and Drug Administration (FDA) has extended Cabenuva's indication to adolescents 12 years of age and older weighing at least 35 kg (77 lb).[1][4] The drug is intended as a replacement for stable antiretroviral therapy in patients with viral suppression (HIV-1 RNA less than 50 copies per ml), no history of treatment failure, and no known or suspected resistance to cabotegravir or rilpivirine.[2][4] Cabenuva is given as two intramuscular injections in the buttock by a healthcare professional once a month or once every two months, for up to 6 doses a year.[1][4][10] Daily tablets are effective, but injections may improve adherence, especially in adolescents who have trouble taking regularly.[1] Studies in adults have shown higher satisfaction with Cabenuva than daily pills because it eliminates daily thinking about treatment and hiding HIV status.[1] Cabenuva does not cure HIV, but it helps keep the virus under control and supports the immune system.[3]